|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|5505810||1400279||2017||4 صفحه PDF||سفارش دهید||دانلود کنید|
- NCOA5 is significantly over-expressed in human luminal breast cancer tissues.
- NOCA5 was involved in the progression of luminal breast cancer.
- NCOA5 can predict the progression of luminal breast cancer.
Nuclear receptor coactivator 5 (NCOA5) is known to modulate ERÎ±-mediated transcription and has been found to be involved in the progression of several malignancies. However, the potential correlation between NCOA5 and clinical outcome in patients with luminal breast cancer remains unknown. In the present study, we demonstrated that NCOA5 was significantly up-regulated in luminal breast cancer tissues compared with adjacent non-cancerous tissues both in validated cohort and TCGA cohort. Moreover, Kaplan-Meier analysis indicated that patients with high NOCA5 expression had significantly lower overall survival (PÂ =Â 0.021). Cox regression analysis indicated that the high NOCA5 expression was independent high risk factor as well as old age (>60) and HER-2 expression (PÂ =Â 0.039; PÂ =Â 0.003; PÂ =Â 0.005; respectively). This study provides new insights and evidences that NOCA5 over-expression was significantly correlated with progression and prognosis in luminal breast cancer. However, the precise cellular mechanisms for NOCA5 in luminal breast cancer need to be further explored.
Journal: Biochemical and Biophysical Research Communications - Volume 482, Issue 2, 8 January 2017, Pages 253-256